B of A Securities Maintains Underperform on Integra Lifesciences, Lowers Price Target to $18
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Craig Bijou has maintained an 'Underperform' rating on Integra Lifesciences and lowered the price target from $26 to $18.
October 07, 2024 | 5:12 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
B of A Securities has maintained an 'Underperform' rating on Integra Lifesciences and reduced the price target from $26 to $18, indicating a negative outlook.
The 'Underperform' rating and reduced price target from $26 to $18 by B of A Securities suggest a negative outlook for Integra Lifesciences, likely leading to a short-term decrease in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100